ClinicalTrials.gg
CompletedNCT00265395Updated Apr 5, 2017Results posted

Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)

A Phase 3 interventional study of Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®) and Combination of pegylated interferon alfa-2b and ribavirin in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,428
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
2nd of 39
1,428 · median 99
Started
2004
the only one that year
Phase 3
22 of 40
none open now
Registered
8th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 2nd largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2004, is one of 22 in phase 3, and was the 8th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

This is a controlled, randomized, parallel-groups, open-label, multinational study designed to evaluate the efficacy and safety of PEG-Intron® (pegylated interferon alfa-2b) plus Rebetol® (ribavirin) in subjects with chronic hepatitis C. It is designed to evaluate whether 72 weeks of treatment with PEG-Intron plus Rebetol is more effective than 48 weeks of treatment in subjects with Genotype 1 chronic hepatitis C who exhibit a slow response to treatment.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects aged 18 to 70 years, of either sex.
  • Genotype-1 virus (HCV)-ribonucleic acid (RNA)-positive subjects.
  • Subjects must be willing to give written and able to adhere to dosing and visit schedules.
  • Confirmation of liver availability: Availability of a liver biopsy performed within 18 months prior to the Screen visit, with a pathology report confirming the histological diagnosis of chronic hepatitis or liver cirrhosis.
  • Compensated liver disease with the following minimum hematological, biochemical, and serological criteria at the screen visit (WNL = within normal limits, = Upper Limit Normal):

    • values of equal or more than 12 g/dL for females and 13 g/dL for males.
    • White blood cells (WBCs) equal to or more than 3,000/mm\^3
    • equal to or more than 1,500/mm\^3
    • count equal to or more than 80,000/mm\^3
    • Direct up to 10% above ULN is acceptable.
    • Indirect bilirubin up to 10% above ULN is acceptable (unless non-hepatitis related factors such as Gilbert's disease explain an indirect bilirubin rise). In such cases indirect bilirubin should be less than or equal to 3.0 mg/dL (less than or equal to 51.3 µmol/L)
    • Albumin up to 10% above ULN is acceptable.
    • Serum creatinine up to 10% above ULN is acceptable.
    • (ALT) level above ULN at Screen.
  • At the Screen Visit, fasting glucose must be 70-140 mg/dL. Results between 116-140 mg/dL require repeat fasting glucose to be less than 140 mg/dL and less than or equal to 8.5%. HbA1C must be less than or equal to 8.5% in diabetic subjects (whether on medication or diet controlled).
  • Antinuclear antibodies (ANA) must be less than or equal to 1:320.
  • Thyroid Stimulating Hormone (TSH) WNL whether in euthyroid subjects or subjects requiring medical treatment. (subjects requiring medication to maintain TSH levels within normal limits are eligible if all other inclusion/exclusion criteria are met).
  • Confirmation by the principal investigator or a sub-investigator that sexually active females of are practicing adequate .
  • Female subjects cannot be pregnant or breastfeeding and must be either , surgically sterile or using 2 methods of birth control. While abstinence from sexual activity is the only certain method to prevent pregnancy, female patients of childbearing potential who are or who anticipate the possibility of becoming sexually active with a male partner must use a combination of the following 2 methods :

    • Contraceptive pill or intrauterine device (IUD) or depot hormonal preparation (ring, injection implant) and
    • A barrier method of contraception such as diaphragm, sponge with spermicide, condom, or a method of birth control considered acceptable by the study physician. Contraceptive measures will be reviewed with female subjects at each visit. Dual methods of contraception must be used for 1 month prior to the start of treatment and 6 months after treatment discontinuation.
  • A serum pregnancy test obtained at Screen Visit prior to the initiation of treatment must be negative.
  • Confirmation by the principal investigator or a sub-investigator that sexually active male subjects are practicing a method of contraception considered acceptable (vasectomy, condom plus spermicide, plus relationship with a female partner who practices an acceptable method of contraception). Contraception must be used during the treatment period and for seven months (or 6 months, according to local label) after the completion of therapy, including condom use by male subjects with pregnant partners.
  • For subjects with a history of hypertension or diabetes, written clearance from an ophthalmologist has to be obtained prior to treatment start.

Exclusion criteria

Exclusion Criteria:

  • Pregnant women, women who plan to become pregnant, male subjects whose partner wants to become pregnant, and breastfeeding women.
  • Previous treatment for chronic with an antiviral or immunomodulating agent or with some interferon or ribavirin product, whether alone or in combination.
  • Subjects weighing over 125 kg.
  • Suspected to any interferon or ribavirin product.
  • Participation in other clinical trial within 30 days prior to screen into this study.
  • Coinfection with virus (HBV), (HIV), or both.
  • Any cause of liver disease other than chronic hepatitis C, including but not limited to:

    • Hemochromatosis
    • Alpha-1 antitrypsin deficiency
    • Wilson's disease
    • hepatitis
    • Alcoholic liver disease
    • Non-alcoholic steatohepatitis (NASH)
    • Drug-related liver disease
  • Active malignant disease or suspicion or history of malignant disease within five previous years (except for adequately treated basal cell carcinoma).
  • Known coagulation diseases such as hemophilia; diseases (e.g. thalassemia).
  • Known glucose 6-phosphate dehydrogenase (G6PD) deficiency
  • Evidence of advanced liver disease such as history or presence of ascites, bleeding varices, or hepatic encephalopathy.
  • Subjects with organ transplants, except for corneal or hair transplant.
  • Any known preexisting medical condition that could interfere with the subject's participation in and completion of study, such as:

    • Preexisting psychiatric condition, especially moderate to severe depression, or a history of severe psychiatric disorder, such as psychosis, suicidal ideation, or suicide attempts. Severe depression includes the following:

      • Hospitalization for depression
      • Electroconvulsive therapy for depression, or
      • Depression causing a prolonged absence from work or significantly altering daily functions.
    • Subjects with mild depression may be considered for entry into the study provided that a pre-treatment assessment demonstrates that the subject's emotional status is clinically stable, in which case a management plan must be formulated for the subject; this management plan will become a part of the subject's medical record.
    • Craniocerebral trauma which is not a concussion, or active seizure disorders requiring medication.
    • (ECG) abnormalities and/or cardiovascular dysfunction within 6 previous months (e.g., angina, congestive heart failure, recent myocardial infarction, or significant arrhythmia).
    • Chronic lung disease (e.g., chronic obstructive lung disease)
    • Poorly controlled diabetes mellitus
    • Immune-mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis)
    • Clinical gout
  • Subject is or was a substance abuser, such as alcohol (80 g/day or more), methadone, intravenous(IV), oral or inhaled drugs. To be considered for inclusion into the protocol, the subject must have abstained and agree to abstain from using any of the above for at least 6 months. Subjects treated with buprenorphine (Subutex) who have been stable for 6 months may be included.
  • Cirrhotic subjects whose ultrasound confirms hepatocellular carcinoma.
  • Any other condition that, in the investigator's opinion, could determine that subject's participation in the study is not indicated or could interfere with the subject's participation in and completion of study.
  • Subjacent disease that potentially would require systematic administration of
  • Insulin dependent diabetes mellitus
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,428 participants (actual)

Study arms

  • Active comparator
    Standard therapy

    Slow responders (defined as being polymerase chain reaction \[PCR\] positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to stop treatment at Week 48.

    Drug: Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)

  • Experimental
    Extended therapy

    Slow responders (defined as being PCR positive at Week 12 with at least 2 log reduction in viral load and PCR negative at Week 24) who are randomized at Week 48 to continue treatment to Week 72.

    Drug: Combination of pegylated interferon alfa-2b and ribavirin

Interventions

  • DrugCombination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)

    Drug page: Peginterferon alfa-2b

    1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks 2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks

    Also known as: (a) SCH 54031; PEG-Intron; PegIntron; ViraferonPeg., (b) SCH 18908; Rebetol; REBETOL.

  • DrugCombination of pegylated interferon alfa-2b and ribavirin

    Drug pages: Peginterferon alfa-2b · Ribavirin

    1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks. 2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks

    Also known as: (a) SCH 54031; PEG-Intron; PegIntron; ViraferonPeg., (b) SCH 18908; Rebetol; REBETOL.

06

What researchers measure

Primary outcomes

  1. Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.

    LLQ = 30 IU/mL by reverse transcription polymerase chain reaction (RT-PCR) (Taqman Roche)

    Time frame: 48 or 72 weeks of treatment plus 24 weeks of follow-up.

07

Results

Posted Jul 8, 2009

Participant flow

Participant flow — Overall Study
MilestoneStandard Therapy (48-week Treatment)Extended Therapy (72-week Treatment)
Started8673
Completed7856
Not completed817
Withdrew: Adverse event36
Withdrew: Lost to follow-up21
Withdrew: Withdrawal by subject16
Withdrew: Protocol violation22
Withdrew: Lack of efficacy01
Withdrew: Administrative01

Outcome measures

PrimarySustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.

LLQ = 30 IU/mL by reverse transcription polymerase chain reaction (RT-PCR) (Taqman Roche)

Time frame:
48 or 72 weeks of treatment plus 24 weeks of follow-up.
Reported as:
Number · Participants
Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.
ParticipantsStandard Therapy (48-week Treatment)Extended Therapy (72-week Treatment)
Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.3735
Statistical analysis
  • Standard Therapy (48-week Treatment) vs Extended Therapy (72-week Treatment) · Asymptotic Z-test · p = 0.6445 · Svr rate difference: -4.9 · 95% CI -20.4 to 10.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Standard Therapy (48-week Treatment)—93/1,427 (6.5%)1,337/1,427 (93.7%)
Most frequent serious events
Showing 10 of 122
Most frequent serious events
EventStandard Therapy (48-week Treatment)
NAUSEAGastrointestinal disorders4/1427
ASTHENIAGeneral disorders4/1427
APPENDICITISInfections and infestations4/1427
PNEUMONIAInfections and infestations4/1427
DEPRESSIONPsychiatric disorders4/1427
SYNCOPENervous system disorders3/1427
SUICIDE ATTEMPTPsychiatric disorders3/1427
ANAEMIABlood and lymphatic system disorders2/1427
BRADYCARDIACardiac disorders2/1427
VERTIGOEar and labyrinth disorders2/1427
Most frequent other events
Showing 10 of 35
Most frequent other events
EventStandard Therapy (48-week Treatment)
INFLUENZA LIKE ILLNESSGeneral disorders599/1427
PYREXIAGeneral disorders421/1427
HEADACHENervous system disorders408/1427
ASTHENIAGeneral disorders402/1427
FATIGUEGeneral disorders338/1427
ALOPECIASkin and subcutaneous tissue disorders318/1427
NEUTROPENIABlood and lymphatic system disorders281/1427
MYALGIAMusculoskeletal and connective tissue disorders274/1427
PRURITUSSkin and subcutaneous tissue disorders267/1427
NAUSEAGastrointestinal disorders254/1427

Baseline characteristics

Age, Continuous
Age, Continuous(years)Standard Therapy (48-week Treatment)Extended Therapy (72-week Treatment)Total
Mean44.5 ± 9.946.5 ± 11.645.35 ± 10.79
Sex: Female, Male
Sex: Female, Male(Participants)Standard Therapy (48-week Treatment)Extended Therapy (72-week Treatment)Total
Female342761
Male524698
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, Sarrazin C, Balciuniene L, Feinman SV, Faruqi R, Pedicone LD, Esteban R; SUCCESS Study Investigators. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010 Oct;52(4):1201-7. doi: 10.1002/hep.23816. PubMed 20683847 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2005
First posted
Dec 14, 2005
Start
Dec 2004
Primary completionActual
May 2008
CompletionActual
May 2008
Results first posted
Jul 8, 2009
Last update
Apr 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00265395
Responsible party
Sponsor
First posted
Dec 14, 2005
Start date
Dec 2004
Primary completion
May 2008
Completion
May 2008
Results posted
Jul 8, 2009
Last update
Apr 5, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion